NeuShen Therapeutics

Focus: NeuShen Therapeutics is a Shanghai-based biotechnology company focused on AAV gene therapy and small molecule development. The company is in early-stage development with minimal clinical activity to date.

Gene Therapy

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About NeuShen Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow NeuShen Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Placebo

Healthy Subjects

Phase 1

Clinical Trials (1)

NCT06345703First-into-human Study of NS-136 in Healthy Subjects

Phase 1

Help build intelligence for NeuShen Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to build from ground level in emerging AAV gene therapy space with potential for outsized impact in a high-growth modality
Rare early-stage position in China's biotech ecosystem, which may offer less saturated career progression pathways than Western markets
Cross-functional hiring across discovery, clinical, and operations suggests a scaling organization open to diverse skill sets

Watch Out For

Extremely limited clinical validation with only one Phase 1 trial in healthy subjects—no proof of concept or efficacy data available
Lack of disclosed funding, revenue, cash position, or financial metrics creates visibility gap regarding company runway and stability
Only 4 active job openings and no headcount data suggest either very early stage or very small organization with limited career mobility

Generated by Claude from NeuShen Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NS-136

Schizophrenia(Acute)

Phase 2

Clinical Trials (1)

NCT07521683A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia

Phase 2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Top TAs: Neurology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Neurology

1 pipeline

Marketed

Pipeline